Lytix Biopharma's LTX-315 Demonstrates Strong Efficacy in Skin Cancer Trials, Eyes Phase III
Key Insights
Lytix Biopharma (search)'s LTX-315 showed an impressive 97% objective response rate in a Phase II study for basal cell carcinoma (search), potentially as a first-line treatment.
Interim data from the ATLAS-IT-05 trial revealed a 40% disease control rate in late-stage melanoma (search) patients, with some stabilization lasting up to 22 months.
A new Phase II NeoLIPA study has begun, evaluating LTX-315 with pembrolizumab in early-stage melanoma (search) patients with strong immune systems.
Lytix Biopharma (search) is making strides in cancer treatment with its lead drug candidate, LTX-315. Recent clinical results demonstrate promising efficacy, particularly in skin cancers like basal cell carcinoma (search) (BCC) and melanoma (search). The company is advancing towards potential Phase III trials and further clinical development.
Positive Results in Basal Cell Carcinoma
Lytix Biopharma (search)'s licensing partner, Verrica Pharmaceuticals, reported a 97% objective response rate in patients treated with LTX-315 for basal cell carcinoma (search). This data, presented at the DNB Nordic Healthcare conference, underscores LTX-315's potential as a first-line therapy for BCC, the most common cancer type globally. Earlier data showed an 86% overall reduction in tumor size and a 51% complete clearance rate.
Advancements in Melanoma Treatment
In the ATLAS-IT-05 Phase II trial, LTX-315 demonstrated a 40% disease control rate in late-stage melanoma (search) patients who had been heavily pre-treated. Disease stabilization was observed for up to 22 months in some patients. Furthermore, a new Phase II study, NeoLIPA, has commenced at Oslo University Hospital, Radiumhospitalet, targeting early-stage melanoma patients. This study combines LTX-315 with pembrolizumab, an immune checkpoint inhibitor, prior to surgery.
"Melanoma (search) patients often experience relapse following surgery when treated with the standard of care today. Our technology arms the immune system and complements today’s treatment options to prevent the cancer from spreading and recurring at a later stage, in addition to kill cancer cells in the locally treated lesions," said Dr. Øystein Rekdal, CEO of Lytix Biopharma (search).
Financial Stability and Future Plans
Lytix Biopharma (search) has strengthened its financial position by securing NOK 111 million through a private placement and a PrimaryBid offering. This funding will support key clinical milestones, including discussions with the FDA regarding Phase III trials for LTX-315 in the first half of 2025. The company's cash reserves totaled NOK 131 million at the end of Q4 2024.
Further Developments
Lytix is also developing a new formulation of LTX-401, which has demonstrated improved anticancer effects and an extended patent life. Clinical trials for this formulation are planned for 2026. Additionally, the company secured a U.S. patent for LTX-315 in combination with PD-1 inhibitors (search), further solidifying its intellectual property portfolio.